Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

By A. Daud, R. Deconti, S. Andrews, P. Urbas, A. Riker, V. Sondak, P. Munster, D. Sullivan, K. Ugen, J. Messina and 1 more. Journal of Clinical Oncology, 2008

671 citations recorded by the source corpus.

Subfields: Biotechnology, Immunology

View Paper: https://www.semanticscholar.org/paper/317de658b16bb3dd9b0e00cd35a5f5cc69a300dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

1. Ralph Weissleder
2. M. Pittet

In Immunology

1. M. Pittet
2. G. Freeman
3. M. Jakóbisiak
4. Ralph Weissleder
5. Witold Lasek
6. R. Zagożdżon
7. Sylvia M. Lee
8. K. Margolin

Citations in the corpus

• Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 (2018, positive): “However, targeted intratumoral delivery of IL12-encoding plasmids is safe and has already demonstrated antitumor efficacy as monotherapy (Daud et al., 2008).”
• Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “In 53 % patients, there was evidence of systemic response and three patients experienced complete response (of note, one of these patients was additionally treated with dacarbazine) [165].”
• Cytokines in Cancer Immunotherapy (2011, background): “appears to have the potent ability to induce counterregulatory cytokines such as IL-10 that may abrogate its immunostimulatory properties, depending on the dose and schedule of administration, but it may have promise as a component of the immune adjuvant in certain tumor vaccine strategies as well a”